Boston Sci reports good data for Farapulse, Watchman afib systems

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17. In late-breaking data presentations, the ADVANTAGE AF trial for the ... Read More

Boston Scientific reports outcomes from Farapulse and Farapoint trial

Boston Scientific has reported positive 12-month primary endpoint outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse pulsed field ablation (PFA) system and Farapoint PFA ... Read More

Boston Scientific Reports Positive Results from Atrial Fibrillation Device

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ... Read More

Boston Sci stock climbs 5% on positive Watchman FLX data

Boston Scientific (NYSE:BSX) stock climbed 5% Monday after the medical device maker announced a study has shown its Watchman FLX device was superior to oral anti-coagulant medication in reducing ... Read More

Buy Recommendation for Boston Scientific Driven by Promising Watchman FLX Data and Growth Prospects

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed from Bank of America Securities maintained a Buy rating on ... Read More

Boston Scientific's (BSX) FARAPULSE System Study Data Positive

Boston Scientific Corporation BSX recently presented positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE Pulsed Field Ablation (PFA) System -- a nonthermal treatment in ... Read More